Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors

International Journal of Neuropsychopharmacology

Volumn 13, Issue 10, 2010, Pages 1299-1314

  Bortolozzi, Analía ^a,b   Masana, Mercè ^a,b   Díaz Mataix, Lloreñ ^a   Cortés, Roser ^a,c   Scorza, María Cecilia ^a   Gingrich, Jay A ^d   Toth, Miklos ^e   Artigas, Francesc ^a,b  

^a INST D INVESTIGACIONS B   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^d Columbia University ^*  (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

5 HT1A receptor; 5 HT2A receptor; Antipsychotic drugs; dopamine; prefrontal cortex

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; G PROTEIN COUPLED RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OLANZAPINE; RISPERIDONE; RITANSERIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; KNOCKOUT MOUSE; MICRODIALYSIS; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; ANIMAL; ANIMAL MODEL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOUSE MUTANT; SCHIZOPHRENIA; WISTAR RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOPAMINE; DOPAMINE ANTAGONISTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRODIALYSIS; MODELS, ANIMAL; PREFRONTAL CORTEX; QUINOLINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, G-PROTEIN-COUPLED; RISPERIDONE; SCHIZOPHRENIA;

EID: 79952639595     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571000009X     Document Type: Article

References (82)

1. Aghajanian GK, Marek GJ (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36, 589-599. (Pubitemid 27272104)
2. Akil M, Pierri JN, Whitehead RE, Edgar CL, et al. (1999). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. American Journal of Psychiatry 156, 1580-1589. (Pubitemid 29459991)
3. Amargös-Bosch M, Bortolozzi A, Adell A, Artigas F (2003). Stimulation of a1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release. Reversal by antipsychotics drugs. Journal of Neurochemistry 87, 831-842. (Pubitemid 37444559)
4. Amargös-Bosch M, Bortolozzi A, Puig MV, Serrats J, et al. (2004). Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cerebral Cortex 14, 281-299. (Pubitemid 38252721)
5. Araneda R, Andrade R (1991). 5-Hydroxytryptamine-2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40, 399-412.
6. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18, 63-101. (Pubitemid 28026679)
7. Artaloytia JF, Arango C, Lahti A, Sanz J, et al. (2006). Negative signs and symptoms secondary to antipsychotics : a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. American Journal of Psychiatry 163, 488-493. (Pubitemid 44469392)
8. Ashby CR, Edwards E, Wang RY (1994). Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex : an iontophoretic study. Synapse 17, 173-181. (Pubitemid 24204343)
9. Assie? MB, Ravailhe V, Faucillon V, Newman-Tancredi A (2005). Contrasting contribution of 5-hydroxytryptamine1A receptor activation to neurochemical profile of novel antipsychotics : frontocortical dopamine and hippocampal serotonin release in rat brain. Journal of Pharmacology and Experimental Therapeutics 315, 265-272. (Pubitemid 41380520)
10. Bantick RA, Deakin JF, Grasby PM (2001). The 5-HT1A receptor in schizophrenia : a promising target for novel atypical neuroleptics? Journal of Psychopharmacology 15, 37-46. (Pubitemid 32242102)
11. Battaglia G, Norman AB, Creese I (1987). Differential serotonin2 receptor recovery in mature and senescent rat brain after irreversible receptor modification : effect of chronic reserpine treatment. Journal of Pharmacology and Experimental Therapeutics 243, 69-75. (Pubitemid 17162699)
12. Bonaccorso S, Meltzer HY, Li Z, Dai J, et al. (2002). SR46349-B, a 5-HT2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 27, 430-441. (Pubitemid 35253790)
13. Bortolozzi A, Amargös-Bosch M, Adell A, Díaz-Mataix L, et al. (2003). In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT2A receptors : effect of antipsychotic drugs. European Journal of Neuroscience 18, 1235-1246. (Pubitemid 37120471)
14. Bortolozzi A, Díaz-Mataix L, Corte?s R, Scorza C, et al. (2007a). Clozapine increases dopamine output in medial prefrontal cortex by a 5-HT2A receptor-independent mechanism. Society for Neuroscience, Abstract 499. 12.
15. Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, et al. (2005). The activation of 5-HT2A receptors in prefrontal cortex enhances dopaminergic activity. Journal of Neurochemistry 95, 1597-1607. (Pubitemid 41804057)
16. Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, et al. (2007b). In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berlin) 191, 745-758. (Pubitemid 46355906)
17. Braff DL (1993). Information processing and attention dysfunctions in schizophrenia. Schizophrenia Bulletin 19, 233-259. (Pubitemid 23183147)
18. Bubenikova-Valesova V, Stuchlik A, Svoboda J, Bures J, et al. (2008). Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task. Proceedings of National Academic of Sciences USA 105, 1061-1066. (Pubitemid 351282081)
19. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96. (Pubitemid 26053226)
20. Carr DB, Sesack SR (2000). Projections from the rat prefrontal cortex to the ventral tegmental area : target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. Journal of Neuroscience 20, 3864-3873. (Pubitemid 30266247)
21. Chemel BR, Roth BL, Armbruster B, Watts VJ, et al. (2006). WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berlin) 188, 244-251. (Pubitemid 44371162)
22. Chou YH, Halldin C, Farde L (2003). Occupancy of 5-HT1A receptors by clozapine in the primate brain : a PET study. Psychopharmacology (Berlin) 166, 234-240. (Pubitemid 36384769)
23. Chung YC, Li Z, Dai J, Meltzer HY, et al. (2004). Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Research 1023, 54-63. (Pubitemid 39195334)
24. Cox RF, Waszczak BL (1993). Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2- dihydroquinoline. Brain Research 613, 32-42. (Pubitemid 23170350)
25. Díaz-Mataix L, Artigas F, Celada P (2006). Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist. European of Neuropsychopharmacology 16, 288-296.
26. Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, et al. (2005). Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity : role in atypical antipsychotic action. Journal of Neuroscience 25, 10831-10843. (Pubitemid 41692613)
27. Elsworth JD, Jentsch JD, Morrow BA, Redmond Jr. DE, et al. (2008). Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine. Neuropsychopharmacology 33, 491-496.
28. Elvevag B, Goldberg TE (2000). Cognitive impairment in schizophrenia is the core of the disorder. Critical Reviews in Neurobiology 14, 1-21. (Pubitemid 32193047)
29. Fiorica-Howells E, Hen R, Gingrich J, Li Z, et al. (2002). 5-HT2A receptors : location and functional analysis in intestines of wild-type and 5-HT2A knockout mice. American Journal of Physiology, Gastrointestinal and Liver Physiology 282, G877-993.
30. Franklin KBJ, Paxinos G (1997). The Mouse Brain in Stereotaxic Coordinates. San Diego, USA: Academic Press.
31. Gessa GL, Devoto P, Diana M, Flore G, et al. (2000). Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology 22, 642-649. (Pubitemid 30219407)
32. Gobert A, Millan MJ (1999). Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38, 315-317. (Pubitemid 29073553)
33. Gozlan H, Laporte AM, Thibault S, Schechter LE, et al. (1994). Differential effects of N-ethoxycarbonyl-2-ethoxy- 12-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain. Neuropharmacology 33, 423-431. (Pubitemid 24168713)
34. Grayson B, Idris NF, Neill JC (2007). Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Research 184, 31-38. (Pubitemid 47404650)
35. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophrenia Bulletin 26, 119-136.
36. Harvey PD, Sacchetti E, Galluzzo A, Romeo F, et al. (2008). A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophrenia Research 105, 138-143.
37. Hemsley KM, Crocker AD (2001). Changes in muscle tone are regulated by D1 and D2 dopamine receptors in the ventral striatum and D1 receptors in the substantia nigra. Neuropsychopharmacology 25, 514-526. (Pubitemid 32830956)
38. Homayoun H, Moghaddam B (2007). Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biological Psychiatry 61, 679-687. (Pubitemid 46328858)
39. Ichikawa J, Ishii H, Bonaccorso S, O'Laughlin IA, et al. (2001). 5-HT2A and D2 receptor blockade increases cortical DA release via of 5-HT1A receptor activation : a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76, 1521-1531. (Pubitemid 32198256)
40. Kargieman L, Santana N, Mengod G, Celada P, et al. (2007). Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proceeding of National Academic of Science USA 104, 14843-14848. (Pubitemid 350003230)
41. Keck BJ, Lakoski JM (2000). Regional heterogeneity of serotonin(1A) receptor inactivation and turnover in the aging female rat brain following EEDQ. Neuropharmacology 39, 1237-1246. (Pubitemid 30173187)
42. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 288, 774-781. (Pubitemid 29119694)
43. Leucht S, Corves C, Arbter D, Engel RR, et al. (2009). Second-generation versus first generation antipsychotic drugs for schizophrenia : a meta-analysis. Lancet 373, 31-41.
44. Lewis DA, Lieberman JA (2000). Catching up on schizophrenia : natural history and neurobiology. Neuron 28, 325-334.
45. Li Z, Prus AJ, Dai J, Meltzer HY (2009). Differential effects of M1 and 5-HT1A receptors on atypical antipsychotics drug-induced dopamine efflux in the medial prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics 330, 948-955.
46. Lie?geois JF, Ichikawa J, Meltzer HY (2002). 5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Research 947, 157-165.
47. Löpez-Gime?nez JF, Mengod G, Palacios JM, Vilarö MT (1997). Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907.
48. Naunyn Schmiedebergs Archives of Pharmacology 356, 446-454.
49. Löpez-Gime?nez JF, Tecott LH, Palacios JM,Mengod G, et al. (2002). Serotonin 5-HT2C receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. Journal of Neuroscience Research 67, 69-85.
50. Martel JC, Leduc N, Ormière AM, Faucillon V, et al. (2007). WAY-100635 has high selectivity for serotonin 5-HT1A versus dopamine D(4) receptors. European Journal of Pharmacology 574, 15-19. (Pubitemid 47503165)
51. Martín-Ruiz R, Puig MV, Celada P, Shapiro DA, et al. (2001). Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate dependent mechanism. Journal of Neuroscience 21, 9856-9866. (Pubitemid 34184070)
52. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics 251, 238-246.
53. Meltzer HY, Sumiyoshi T (2008). Does stimulation of 5-HT1A receptors improve cognition in schizophrenia. Behavioral Brain Research 195, 98-102.
54. Mengod G, Vilarö MT, Raurich A, Löpez-Gime?nez JF, et al. (1996). 5-HT receptors in mammalian brain : receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochemical Journal 28, 747-758. (Pubitemid 26414165)
55. Millan MJ (2000). Improving the treatment of schizophrenia : focus on serotonin 5-HT1A receptors. Journal of Pharmacology and Experimental Therapeutics 295, 853-861.
56. Minabe Y, Hashimoto K, Watanabe KI, Ashby Jr. CR (2001). Acute and repeated administration of the selective 5-HT2A receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study. Synapse 40, 102-112.
57. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, et al. (1998). Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors : a [35S]GTPgammaS binding study. European Journal of Pharmacology 355, 245-256. (Pubitemid 28404707)
58. Nyberg S, Dencker SJ, Malm U, Dahl ML, et al. (1998). D2 and 5-HT2 receptor occupancy in high-dose neuroleptic-treated patients. International Journal of Neuropsychopharmacology 1, 95-101. (Pubitemid 128538369)
59. Parks CL, Robinson PS, Sibille E, Shenk T, et al. (1998). Increased anxiety of mice lacking the 5-HT1A receptor. Proceedings of National Academic of Sciences USA 95, 10734-10739.
60. Pazos A, Corte?s R, Palacios JM (1985). Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Research 346, 231-249. (Pubitemid 16241112)
61. Paxinos G, Watson C (2005). The Rat Brain in Stereotaxic Coordinates, 5th edn. Sydney, Australia : Academic Press.
62. Pehek EA, McFarlane HG, Maguschak K, Price B, et al. (2001). M100,907, a selective 5-HT2A antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Research 888, 51-59. (Pubitemid 32056261)
63. Popa D, Le?na C, Fabre V, Prenat C, et al. (2005). Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. Journal of Neuroscience 25, 11231-11238. (Pubitemid 43083697)
64. Puig MV, Artigas F, Celada P (2005). Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cerebral Cortex 15, 1-14. (Pubitemid 40019048)
65. Puig MV, Celada P, Díaz-Mataix L, Artigas F (2003). In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors : relationship to thalamocortical afferents. Cerebral Cortex 13, 870-882. (Pubitemid 36917967)
66. Re?nyi L, Evenden JL, Fowler CJ, Jerning E, et al. (2001). The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3- (N-isopropyl- Npropylamino)-2H-1-benzopyran arboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist. Journal of Pharmacology and Experimental Therapeutics 299, 883-893. (Pubitemid 33104955)
67. Rollema H, Lu Y, Schmidt AW, Sprouse JS, et al. (2000). 5-HT1A receptor activation contributes to ziprasidoneinduced dopamine release in the rat prefrontal cortex. Biological Psychiatry 48, 229-237. (Pubitemid 30618995)
68. Rollema H, Lu Y, Schmidt AW, Zorn SH (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. European Journal of Pharmacology 338, R3-R5. (Pubitemid 27507749)
69. Roth BL, Shefflerb D, Potkin SG (2003). Atypical antipsychotic drug actions : unitary or multiple mechanisms for 'atypicality'? Clinical Neuroscience Research 3, 108-117. (Pubitemid 36975299)
70. Santana N, Bortolozzi A, Serrats J, Mengod G, et al. (2004). Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cerebral Cortex 14, 1100-1109. (Pubitemid 39258165)
71. Schwieler L, Erhardt S (2003). Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology 28, 1770-1777. (Pubitemid 41070842)
72. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, et al. (1993). Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. Journal of Pharmacology and Experimental Therapeutic 266, 1374-1384. (Pubitemid 24175781)
73. Sumiyoshi C, Sumiyoshi T, Roy A, Jayathilake K, et al. (2006). Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. International Journal of Neuropsychopharmacology 9, 677-683. (Pubitemid 46122767)
74. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, et al. (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. American Journal of Psychiatry 158, 1722-1725. (Pubitemid 32923670)
75. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, et al. (2001b). The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biological Psychiatry 49, 861-868. (Pubitemid 32436390)
76. Yasuno F, Suhara T, Nakayama T, Ichimiya T, et al. (2003). Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. American Journal of Psychiatry 160, 334-340. (Pubitemid 41110460)
77. Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, et al. (1999). Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20, 403-412. (Pubitemid 29123868)
78. Va?zquez-Borsetti P, Corte?s R, Artigas F (2009). Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cerebral Cortex 19, 1678-1686.
79. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, et al. (2007). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nature Neuroscience 10, 376-384.
80. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, et al. (2000). Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Archives of General Psychiatry 57, 907-913.
81. Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572-575.
82. Woodward ND, Purdon SE, Meltzer HY, Zal DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 8, 457-472. (Pubitemid 41002500)